Phoenix Solutions AS is a Norwegian, innovative start-up biotech company. The company is focused on the development of a technology platform for ultrasound mediated, targeted delivery of drug therapies - Acoustic Cluster Therapy - ACT. (tm). The concept is based on a microparticle formulation system for i.v. administration, which is activated in-vivo by diagnostic ultrasound to provide enhanced uptake and distribution of drugs in target tissue. The technology provides a method for efficient and targeted delivery of drugs such as chemotherapeutics, hence enhancing efficacy, whilst minimising general systemic exposure and resulting side effects.

Phoenix Solution was established as a spin out of technology and senior scientists from GE Healthcare. The company currently operates from GE`s Oslo site with state-of -the art lab facilities and commercial scale manufacturing capability.


Phoenix Solutions develops a platform concept enhancing the therapeutic index and thus clinical utility of a wide range of drugs, from small molecules to nanodrugs. We aim to partner with drug companies in need of our IP protected technology.


Preliminary preclinical studies have shown that ACTâ„¢ treatment can induce up to a 10-fold reduction in the growth rate of prostate and pancreatic tumours vs. drug alone (download our Company Flyer for details). Mechanistic studies have shown that ACTâ„¢ treatment can increase tumour specific uptake of co-injected molecules as much as 2-300% and that the concept can be applied for controlled opening of the Blood Brain Barrier. Further optimisation is expected to increase effect levels significantly.

Organisasjonsnr.: 998317487


The phoenix hope, can wing her way through the desert skies, and still defying fortune's spite; revive from ashes and rise. - Miguel De Cervantes.